Skip to main content
A-LevelBiologyGenetic technology9700/43 · Oct/Nov 2019 · Q315 Marks

3 Therapeutic proteins are used to treat disease. One example of a therapeutic protein is human growth hormone (hGH). hGH has important roles in growth during childhood and in regulation of metabolism in adulthood. Children described as hGH-deficient do not produce enough hGH and grow more slowly than other children. People who were hGH-deficient when they were children have a mean adult height that is 32 cm shorter than the population mean. Daily injections of hGH are a treatment for hGH-deficient children that can increase growth rate, resulting in an increased adult height. (a) The growth rate of three children was measured. • The growth rate of the hGH-deficient child who did not receive daily hGH injections was 2.5cm year-1. • The growth rate of the hGH-deficient child who received daily hGH injections was 10.0cm year-¹ in the first year after starting treatment. • The growth rate of the child who is not hGH-deficient was 5.0cm year-1. Calculate the percentage increase in growth rate of the hGH-deficient child treated with hGH injections compared to the child who is not hGH-deficient. Show your working. When this form of treatment started in 1958, hGH could only be obtained from the pituitary glands of people who had died. In 1981, a plasmid containing hGH cDNA was constructed and inserted into Escherichia coli bacteria. This allowed recombinant hGH protein to be produced by the bacteria. (b) Name the type of enzyme that: • cuts plasmid DNA • makes cDNA from hGH mRNA. (c) Identify and explain two properties of plasmids that allow them to be used as vectors of hGH cDNA into cells of Escherichia coli. (d) In 1985, several cases of a rare brain disease were discovered in people who had been treated many years previously with hGH obtained from pituitary glands. It was decided, from 1985 onwards, that only recombinant hGH should be used to treat patients. Explain the advantages of producing human therapeutic proteins, such as hGH, by recombinant DNA technology. (e) hGH is one of many proteins in the body whose secretion or production is controlled by a person's sleep-wake pattern. The sleep-wake pattern describes when, during a 24 hour day, a person is asleep and when they are awake. For example: : pattern 1 - asleep during the night and awake during the day (normal) pattern 2 - asleep during the day and awake during the night. Researchers used microarray analysis to identify which genes have their expression changed by a person's sleep-wake pattern. They collected mRNA from: • a group of people with sleep-wake pattern 1 • the same group of people whose sleep-wake pattern was changed to pattern 2. A summary of the results is shown in Table 3.1. [Table 3.1] (e)(i) Describe how changing the sleep-wake pattern from pattern 1 to pattern 2 affects the number of genes expressed. (e)(ii) Explain how eukaryotic genes can be switched on and off, for example, at certain times of day. (e)(iii) Explain how bioinformatics can help to identify whether the genes whose expression is changed by moving from pattern 1 to pattern 2 are important to health.

  1. (a)Calculate the percentage increase in growth rate of the hGH-deficient child treated with hGH injections compared to the child who is not hGH-deficient. Show your working.[2]
  2. (b)Name the type of enzyme that: • cuts plasmid DNA • makes cDNA from hGH mRNA.[2]
  3. (c)Identify and explain two properties of plasmids that allow them to be used as vectors of hGH cDNA into cells of Escherichia coli.[2]
  4. (d)Explain the advantages of producing human therapeutic proteins, such as hGH, by recombinant DNA technology.[4]
  5. (e)(i)Describe how changing the sleep-wake pattern from pattern 1 to pattern 2 affects the number of genes expressed.[1]
  6. (e)(ii)Explain how eukaryotic genes can be switched on and off, for example, at certain times of day.[2]
  7. (e)(iii)Explain how bioinformatics can help to identify whether the genes whose expression is changed by moving from pattern 1 to pattern 2 are important to health.[2]

This question uses a diagram from the original paper, which isn't shown here. Open the full paper from the past papers archive to see it.

Mark scheme

Marking points from the official mark scheme (Oct/Nov 2019). The mark or mark type is shown in brackets.

  1. [1] (10-5)/5 × 100 ;
  2. [1] 100;
  3. [1] restriction, enzyme / endonuclease ;
  4. [1] reverse transcriptase;
  5. [1] small/low mass, so can enter, cells / E. coli (through membrane) ;
  6. [1] self-replicate in cell so multiply / make many copies of, gene ;
  7. [1] have restriction site(s) / can be cut by restriction enzymes, so new gene can, be added / join ;
  8. [1] have, marker / antibiotic resistance / fluorescence / reporter, genes, so, recombinants / transformed cells / cells that took up plasmid, can be recognised ;
  9. [1] have promoter so gene can be, expressed / transcribed ;
  10. [1] circular so, more stable / not damaged by host cell enzymes ;
  11. [1] prevents / less / lower, (named) disease / infection / pathogen transmission, risk ;
  12. [1] large / unlimited, supply OR mass production (from engineered bacteria) ;
  13. [1] cost of, purification / processing, lower ;
  14. [1] lower risk of, allergy / immune reaction / rejection / side effects ;
  15. [1] potential to, engineer / improve, recombinant proteins ;
  16. [1] fewer genes, expressed / have increased expression;
  17. [1] transcription factors ;
  18. [1] (help / stop), binding / functioning, of RNA polymerase ;
  19. [1] ref. promoter ;
  20. [1] AVP ; light, is detected (by eyes) / causes changes melatonin enhancer / silencer, (DNA) sequences signalling, molecules / pathways
  21. [1] idea of compare with known, genes / sequences / genomes, in database ;
  22. [1] search / analysis, programme / software / algorithm ;
  23. [1] identify, role of protein / (named) health effects ;

Write your answer and get it marked

On Oracle Prep you can write or photograph your own answer and have it marked by AI against this mark scheme, with feedback on what you missed.

Sign up free →

About this question

Topic
Genetic technology, A-Level Biology (syllabus 9700). Structured question, 15 marks.
Source
A-Level Biology, Oct/Nov 2019 Paper 4 Variant 3, question 3.

Questions and mark schemes are from past examination papers and remain the copyright of the exam board. How Oracle Prep builds its content

Related Biology questions

© 2026 Oracle Prep